Randomized Conversion of Calcinurin-Inhibitors (Tacrolimus to Sirolimus) at 6-24 Months Post Transplant in a Prednisone-Free Immunosuppression Regimen: Impact of Incidence of Acute Cellular Rejection, Renal Allograft Function and T Cell Function.

Trial Profile

Randomized Conversion of Calcinurin-Inhibitors (Tacrolimus to Sirolimus) at 6-24 Months Post Transplant in a Prednisone-Free Immunosuppression Regimen: Impact of Incidence of Acute Cellular Rejection, Renal Allograft Function and T Cell Function.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs Sirolimus (Primary) ; Mycophenolate mofetil; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 18 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 18 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 13 May 2014 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top